Critical Organ Doses Research Articles

2406: A novel MR-guided treatment planning tool reduces accumulated critical organ dose in prostate cancer

2406: A novel MR-guided treatment planning tool reduces accumulated critical organ dose in prostate cancer

A Multicentric study on a dosimetric comparison of extended SSD technique, VMAT-Based and helical tomotherapy (HT) for total body irradiation (TBI)

PurposeIn study, it was aimed to evaluate the dose volume histograms (DVH) of extended SSD technique, VMAT-based, and helical tomotherapy plans dosimetrically in a multi-institutional context to achieve higher plan quality and to harmonize total body irradiation plans. MethodsFour different clinical centers participated in the study. The CT images of ten patients were used in this study. During the first phase, ten patients enrolled for TBI were planned by multiple centers according to a common protocol. During the second phase, all centers shared their plans’ DVHs. Treatment plans were evaluated according to the critical organ dose limits. Statistical analysis was performed in the SPSS (version 22.0) program (p < 0.05). ResultsIn study, the results indicated that there was a statistically significant and considerable difference in the dose coverage of PTV, beam delivery time and MU, lens doses, and kidney doses between the four techniques (p < 0.001). The mean lung doses of the four centers were below 10 Gy. No significant difference in maximum liver doses between plans was obtained. ConclusionIn conclusion, although four treatment techniques were suitable for TBI treatment, more homogeneous dose distribution, and lower critical organ doses were obtained with the tomotherapy technique. However, treatment time, MU, and dose rate for lung were disadvantages of the tomotherapy technique. When it comes to deciding on the TBI treatment method, it need to be reviewed some important points. It is needed to sufficient data on long-term results to be able to standardize TBI techniques between centers.

Empirical model for a three-dimensional dose verification system and its application in volumetric-modulated arc therapy for heterogeneous and long-target tumors

PurposeTo perform commissioning of the VMAT dose verification system 3DVH from a unique perspective and investigating its clinical applications in unreported cases with heterogeneous organs or long-target tumors. MethodsInitially, the standard ArcCheck calibration process was conducted. Then, the impact of absolute dose calibration values and ArcCheck CT density settings on the accuracy of the 3DVH reconstruction model was assessed. Subsequently, ten lung cancer cases with heterogeneous organ-encased targets and ten cervical cancer cases with large target volumes were selected to receive VMAT treatment with a TrueBeam Linac. Finally, the performance of the 3DVH method in such radiotherapy validations was assessed. ResultsVarious calibration files had distinct impacts on ArcCheck 2D surface dosimetry and 3DVH dose reconstruction, thus requiring separate optimal calibrations files for these two purposes. The 3DVH dose reconstruction mode exhibited the highest accuracy when using the optimal ArcCheck density value of 1.1787 g/cm³ and an absolute dose calibration value of 249.96 cGy. In all test cases, deviations for target Dmean and D95% were within ±4.2% compared to the planned dose, with notable variations in critical organ doses. In structure-based 3D gamma evaluation, differences were observed compared to existing reports. ConclusionsIt's crucial to account for the ArcCheck array calibration and the interplay between CT density settings and absolute dose calibration values to identify the best combination for an optimal 3DVH dose reconstruction model. The performance of 3DVH in verifying VMAT doses for tumors in heterogeneous or longer target areas may exhibit slight variations compared to other regions.

Quality Assessment Radiotherapy Planning of Breast Cancer Patients with Built-In Metal Port Implants

Purpose: To evaluate the quality of radiation planning for breast cancer patients with implants with a built-in metal port. Conduct a quantitative analysis of the quality of planning, assess the dose load on critical organs for this category of patients.Material and methods: Homogeneity and conformity indices were calculated, and dose loads in critical organs were assessed for irradiation plans using 3D conformal RT (3D CRT) technology for 23 breast cancer patients with a built-in metal port implants. Calculations were carried out both taking into account (outlining) the metal port and artifacts from it on CT images, and without taking it into account.Results: Based on the results of the analysis of the calculated values of conformity and homogeneity indices, doses in critical organs of irradiation plans for 23 patients with breast cancer, it was shown that the presence of a metal port and artifacts from it affects the nature of the dose distribution.Conclusions: When creating a 3D CRT treatment plan, it is necessary to delineate the metal port and artifacts and assign true densities.

MR-guided stereotactic radiation therapy for head and neck cancers

PurposeMR-guided radiotherapy (MRgRT) has the advantage of utilizing high soft tissue contrast imaging to track daily changes in target and critical organs throughout the entire radiation treatment course. Head and neck (HN) stereotactic body radiation therapy (SBRT) has been increasingly used to treat localized lesions within a shorter timeframe. The purpose of this study is to examine the dosimetric difference between the step-and-shot intensity modulated radiation therapy (IMRT) plans on Elekta Unity and our clinical volumetric modulated arc therapy (VMAT) plans on Varian TrueBeam for HN SBRT. MethodFourteen patients treated on TrueBeam sTx with VMAT treatment plans were re-planned in the Monaco treatment planning system for Elekta Unity MR-Linac (MRL). The plan qualities, including target coverage, conformity, homogeneity, nearby critical organ doses, gradient index and low dose bath volume, were compared between VMAT and Monaco IMRT plans. Additionally, we evaluated the Unity adaptive plans of adapt-to-position (ATP) and adapt-to-shape (ATS) workflows using simulated setup errors for five patients and assessed the outcomes of our treated patients. ResultsMonaco IMRT plans achieved comparable results to VMAT plans in terms of target coverage, uniformity and homogeneity, with slightly higher target maximum and mean doses. The critical organ doses in Monaco IMRT plans all met clinical goals; however, the mean doses and low dose bath volumes were higher than in VMAT plans. The adaptive plans demonstrated that the ATP workflow may result in degraded target coverage and OAR doses for HN SBRT, while the ATS workflow can maintain the plan quality. ConclusionThe use of Monaco treatment planning and online adaptation can achieve dosimetric results comparable to VMAT plans, with the additional benefits of real-time tracking of target volume and nearby critical structures. This offers the potential to treat aggressive and variable tumors in HN SBRT and improve local control and treatment toxicity.

Feasibility of board tilt angle on critical organs during hippocampus-sparing whole-brain radiotherapy

The objective of this study was to investigate the impact of altering the board angle on critical organ doses during whole-brain irradiation. Tomography images of the head region of the rando phantom were taken at angles of 0°, 10°, 20°, 30°, and 40°. Target volume (PTV) and organ at risk (OAR) contours were created on CT images using RTOG 0933 criteria. Tomography images of the head region of the rando phantom were taken at angles of 0°, 10°, 20°, 30°, and 40°. Target volume (PTV) and critical organ contours were created on CT images using RTOG 0933 criteria. During this comparative study, we aimed to achieve a standardized dose distribution in the PTV. We evaluated the doses received by D2 (minimum dose received by 2% of the target volume), D98 (minimum dose received by 98% of the target volume), D50 (dose received by 50% of the target volume), and organs at risk (OAR) in the PTV using CT scans taken at different angles. Additionally, we compared the homogeneity index (HI), conformity index (CI), and treatment time (MU) values. This method aimed to decrease the dose of the OAR region near the target volume, specifically the hippocampus. Our findings indicate that a board angle of 300 offers the greatest protection in terms of critical organ doses.

Radio-Immune Response of Spatially Fractionated Radiotherapy for VMAT Lattice Plans

To evaluate radio-immune response of spatially fractionated radiotherapy (SFRT) for large tumors using VMAT Lattice technique in terms of tumor volume under irradiation and dose fractionation schemes after SFRT. Eleven patients treated with SFRT from a single institution were retrospectively replanned to deliver 15Gy in single fraction using Lattice technique. High dose regions are defined by multiple spheres with the diameter of 1.25 to 1.5cm and their vertex space of 3.0 to 4.0cm inside of GTV. VMAT plans with multiple arcs were developed for SFRT. Four palliative fractionation regimens of 200cGy x 12 (EQD2 = 24Gy with a/b of 10Gy), 400cGy x 5 (23.3Gy), 600cGy x 3 (24Gy) and 800cGy x2 (24Gy) and four definitive regimens of 200cGy x 24 (EQD2 = 48Gy), 400cGy x 10 (46.7Gy), 600cGy x 6 (48Gy) and 800cGy x 4 (48Gy) were considered for radiotherapy to follow SFRT. Linear quadratic (LQ) model is compared with radio-immune (RI) response model in which the activation of cytotoxic T lymphocytes, tumor immune suppression capability and immunotherapy drugs can be considered. Tumor regrowth time (TRT, time to tumor regrowth to the original volume after treatment) from each model was compared as a measure of benefit achieved from the application of SFRT. The average volume of GTVs in this study was 776cc (range 58-2944cc). Three different SFRT plans (2D GRID technique with conventional collimator, 2D GRID with step & shoot IMRT, and 3D Lattice) were developed for each patient but only Lattice plans were considered in this study since they produced comparable dose modulation inside the tumor but only Lattice significantly reduced skin and critical organ dose. Radio-immune response model always expects longer TRT than LQ model. For palliative regimens, TRT of RI model is longer than that of LQ model by 14.5±9.9, 15.1±10.6, 17.2±12.4, 17.5±12.8 days for each fractionation scheme. When Lattice plan of 15Gy is delivered before the palliative treatment, the difference becomes 25.9±15.3, 31.5±23.3, 36.7±27.6, 37.5±28.5 days. The benefit of SFRT from RI response is only about 10-20 days. Interestingly, RI response is inversely proportional to tumor volume. When curative dose is considered, the difference of TRT is drastically changed from 25.9±9.8, 460.7±285.8, 1180.8±985.7, 1512.0±1327.5 days to 20.7±4.4, 449.0±411.7, 1725.4±2171.0, 3517.7±4531.7 days. The benefit of SFRT from RI response appears larger for large tumor with hypo-fractionation in definitive regimens. The benefit of SFRT is significant for large tumors with hypo fractionation in the definitive regimens when radio-immune response model is considered which is not apparent in LQ model. Radio-immune response model may help to guide the development of successful treatment scheme large tumor volumes.

Knowledge Based Planning for Lung SBRT: Model Transferability between Treatment Systems and Calculation Algorithms

Knowledge based planning (KBP) is known to be effective and clinically feasible in achieving high quality treatment plans with less variability between planners and reduced planning time. A KBP model is highly dependent on characteristics of the training data. Our institution developed and validated a lung SBRT KBP model from plans treated with a C-arm linear accelerator (Linac). This study aims to evaluate the quality of lung SBRT plans with a KBP model when this model is used for an O-ring Linac with different MLC design, beam quality, and calculation algorithm. Two academic hospitals in the same healthcare network were included in this study. One hospital trained a KBP model for five-fraction lung SBRT using 43 plans calculated using the Eclipse AcurosXB v15.6 algorithm for a C-arm Linac. The model was developed to prioritize dose gradient outside the PTV while satisfying institutional critical organ limits and validated using an additional set of 12 plans. A cohort of 10 patients (11 plans) previously treated with lung SBRT using the O-ring Linac at the second hospital was selected. These plans were calculated using the Eclipse AAA v15.6 algorithm with prescription doses of 30-50 Gy in five fractions. Each plan was re-optimized using the KBP model, without manual adjustment of the optimization objectives, using the same beam geometry as in the clinical plans. KBP plans were normalized to achieve the same PTV coverage as the clinical plans. Clinical and KBP plans were evaluated for ITV D98%, PTV conformity index (CI), R50 and maximum dose at 2 cm from the PTV (D2cm). All clinical and KBP plans met critical organ dose constraints. The range of CI was 1-1.13 vs. 0.96-1.05 for clinical plans and KBP plans, respectively. R50 and D2cm were lower with KBP plans (p = 0.007 and p = 0.05, respectively). ITV D98% range was 105-120% vs. 117-122% of the PTV prescription dose for clinical plans and KBP plans, respectively, and higher with KBP plans (p<0.001). For plans where the PTV overlaps the chest wall (n = 7), the maximum chest wall doses (D0.03cc) from KBP plans were higher than the clinical plans (p = 0.16), with an absolute chest wall D0.03cc difference of 9 Gy (54 Gy vs 63 Gy). The KBP model includes an ITV SIB of 120% of the PTV prescription, whereas the clinical plans reduced the ITV SIB when the PTV overlapped the chest wall, highlighting a difference in clinical practice between the two hospitals in this study. This study supports that a lung SBRT KBP model trained using plans for one Linac system and the AcurosXB algorithm can be used to generate clinically acceptable plans without manual planner intervention for a different Linac system and the AAA calculation algorithm, indicating the potential of a KBP model use for centralized planning process across different Linac systems and calculation algorithms.

First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed and Refractory (R/R) Acute Leukemia

Patients with R/R acute leukemia after allogeneic hematopoietic cell transplant (alloHCT) have a dismal prognosis with 3-year survival rates of < 20%. To improve outcomes, innovative targeted forms of organ sparing radiotherapy, such as tumor-specific RIT and TMLI, are needed to dose escalate with acceptable toxicities, especially in patients ≥ age 60 years who cannot tolerate total body irradiation (TBI) / myeloablative regimens and who have a poor prognosis. CD25 is an ideal RIT target given its expression in acute leukemias, association with poor prognosis, and expression by leukemia stem cells. In this phase I trial (NCT05139004) we hypothesized that combining dose escalated 90Y-anti-CD25 RIT with fixed dose TMLI 12 Gy, fludarabine (flu), and melphalan (mel) in patients with R/R disease is safe and associated with acceptable toxicities. The primary objective of this trial is to determine the maximum tolerated dose and recommended phase 2 dose of 90Y-anti-CD25 Mab (Day -15) with 12 Gy TMLI (1.5 Gy twice a day, days -8 to -5), flu (30 mg/m2/d days -5 to -2), and mel (100 mg/m2, day -2) in patients ≥ 60 years old or with a HCT-comorbidity index ≥ 2 and with R/R AML, ALL or myelodysplastic syndrome (MDS) scheduled to undergo alloHCT from a matched donor. TMLI mean organ dose constraints for kidney, lung and liver were 4 Gy. Planned dose levels of 90Y-anti-CD25 were 0.3, 0.4, and 0.5 mCi/kg. 111In-anti-CD25 (5 mCi) was co-infused followed by serial nuclear scans to assess dosimetry and biodistribution. To date 5 patients (ages 31-74) with R/R AML have been treated. Marrow and circulating blasts ranged from 10-36% and 9-44%, respectively. For the 3 patients at 0.3 mCi/kg, follow-up ranged from 89-191+ days. 90Y/111In-anti-CD25 nuclear scans demonstrated persistent uptake in bone out to 144 hours, which was associated with a decline in circulating blasts. After combined RIT and TMLI, mean doses (Gy) to lungs ranged from 5.7-6.5, to kidneys from 7.5-8.2 and to liver from 7.2-11.6. No dose-limiting toxicities (DLT) were observed. All 3 patients achieved CR on day +30 bone marrow biopsies and 2 remained in CR on day +90 biopsies. Two patients have recently been treated at the 0.4 mCi/kg dose level. The results of patients treated at the higher dose levels will be provided. Dose escalation by adding 90Y-anti-CD25 RIT at 0.3 mCi/kg to 12 Gy TMLI was safe, including in older patients, with no dose-limiting toxicities, mean critical organ doses lower than conventional myeloablative TBI, and encouraging response rates. The toxicity profile and dose estimates at 0.3 mCi/kg predict that the planned higher dose levels will also be feasible with acceptable toxicities. RIT and TMLI are complementary and when combined address the limitations of each modality. Combining these targeted therapies may be a superior strategy to intensify dose to leukemia compared to dose escalation of either modality alone.

A personalized Monte Carlo study of tumor and critical organ doses for Trans-arterial Radioembolization patients.

Trans-arterial Radioembolization (TARE) is an intra-arterial treatment method for liver malignancies. In this procedure, the therapeutic tumor dose is significant for predicting the treatment effectiveness while the dose absorbed in an organ at risk provides an understanding of its tolerance to radiation. This study proposes a Monte Carlo (MC) approach for determining absorbed organ doses for patients undergoing TARE treatment. The technique is based on the use of a voxel-based partial body model generated for each patient from his/her anatomical image data to represent the critical body structures more realistically. These structures are first segmented from image slices to create an image block which is then incorporated into a radiation transport package (MCNP6.2) to perform MC simulations. When used along with the parameters specific to a patient's treatment, such as lung-shunt factor (LSF), tumor-to-normal liver ratio (TLR), fractional uptakes, and administered activity, this approach allowed more accurate simulation of radiation interactions and hence provided absorbed doses specific to a TARE patient. The MC method also calculated the absorbed doses in organs or tissues that were close to target tissues for which the MIRD formalism makes no predictions. MIRD calculations were found to overestimate the absorbed doses by as much as 11% in lungs, 5% in liver, and 20% in tumor volumes. This raises concerns about the treatment's efficacy when estimating the correct activity to be administered to a patient. When each patient simulation was repeated with a 90Y source spectrum to reflect the distribution of varying beta energies, the liver and the lungs were observed to receive relatively lower doses than those obtained with monoenergetic beta particles. Thus, it can be stated that the approach adopted in this study offers a more precise model of the patient's critical tissues and serves as a personalized dosimetric tool for TARE treatment planning.

Monte Carlo calculations of critical organ doses in radioembolization therapy of primary liver tumors via 90Y microspheres

Monte Carlo calculations of critical organ doses in radioembolization therapy of primary liver tumors via 90Y microspheres

The effect of breath-hold technique on conformal and intensity modulated radiotherapy techniques at right breast cancer radiotherapy including internal mammarian field

Background/Aim: Significantly lower heart doses can be achieved by breath-hold technique at left-sided breast cancer radiotherapy (RT). We see high doses at organs at risk such as lung, heart, and contralateral breast during right-sided breast cancer RT planning especially in the presence of RT indication for mammaria interna (MI) lymph nodes. This study compared RT-planning methods that are conformal with intensity-modulated RT (IMRT) with breath holding and free breathing for right-sided breast cancer RT including full axillary and MI lymph node fields. Methods: Computed tomography (CT) simulations were performed using free-breath (FB) and breath-hold (BH) methods in 10 patients with right-sided breast cancer. A total of 40 RT treatment plans were calculated. Right-sided breast, level 1-2-3 axillary regions, and MI regions served for the target-planning volume. Left-sided breast, heart, as well as right-sided and left lungs were contoured as critical organs according to the atlas of the "Radiation Therapy Oncology Group." We used a Varian Eclipse v.13 for treatment planning. Conformal “FieldinField” RT (FinFRT) and dynamic IMRT (dIMRT) planning were performed separately for each patient over breath-hold and free-breath images. For PTV, 50 Gy was prescribed in 25 fractions and optimized such that the planned target volume (PTV) remained between 95% and 110% of the dose. The mean and maximum doses of the heart, V5 and V20 of the lungs, as well as V95 doses for MI were recorded. Statistical analyses were performed with SPSS version 22, and a paired t-test was used for comparison. Results: Four treatment plans (FB FinFRT, BH FinFRT, FB dIMRT, BH dIMRT) were made separately for 10 patients. For comparison, common FB FinFRT plans were accepted as the baseline plan. As expected, there were no significant differences in PTV coverage. The mean dose received by 95% of the MI volume was between 42.27 Gy and 42.4 Gy. For the maximum heart dose, the breath hold technique had no significant effect on plans. The lowest average maximum heart dose was seen in the BH FinFRT group. Mean heart doses are between 1.28 Gy – 4.85 Gy. There was no significance between BH FinFRT and FB FinFRT plan (P=0.504), and there was a significant difference for heart mean dose versus dIMRT plans (P=0.001). The mean V20 of the lungs ranged from 11.9 to 17.8. There was a significant decrease in V20 with BH or FB dIMRT plans (P=0.001). There was no difference between BH FinFRT (P=0.138). On the contrary, lung V5 values were significantly higher in dIMRT plans, and the lowest mean V5 value was seen in BH FinFRT plan. Conclusion: With the BH method, lower doses (but not significantly lower doses) were obtained in critical organ doses. There was a significant decrease with FinFRT plans in terms of heart mean and maximum dose and lung V5 percentages. The dIMRT plans were significant only in lung V20 percentages. When planning RT, we recommend evaluating all treatment techniques individually for right-sided breast cancer patients to obtain lower doses in critical organs.

Dosimetric Comparison of Different Radionuclides Used in Metastatic Bone Disease Treatment.

This study aimed to determine the critical organ doses in 223Ra, 89Sr, 153Sm, and 32P treatments via dosimetry using the phantoms. The OpenDose was used to calculate S values (mGy MBq-1s-1) for bone surface, red bone marrow, urinary bladder wall, testes, ovaries, uterus, and kidneys using male (ICRP110AM) and female (ICRP110AF) phantoms. The cortical thoracic spine was modeled as metastasis. Moreover, the absorbed doses were computed via MIRD formalism according to the activities of 3.3, 148, 2220, and 370 MBq for ICRP110AM and 4.015, 148, 2701, and 370 MBq for ICRP110AF in 223Ra, 89Sr, 153Sm, and 32P treatments, respectively. Whilst the maximum bone surface doses were found as 1.22E+02 and 8.51E+01 mGy at 32P treatment, the minimum bone surface doses were calculated as 8.42E-02 and 8.26E-02 mGy at 223Ra. In terms of the comparison of red bone marrow, urinary bladder wall, and kidney doses, 153Sm and 89Sr treatments showed maximum doses of 2.45E-03, 1.50E-03, 3.23E-07, 5.45E-06, 1.20E-01, 1.49E-01 mGy and the minimum doses with 3.46E-05, 1.99E-05, 6.33E-09, 8.77E-09, 1.19E-04, 1.15E-04 mGy, respectively. The maximum testes and ovaries-uterus doses were found as 6.17E-08, 7.40E-06, 3.46E-07 mGy in 153Sm treatment, and minimum testes and ovaries doses as 1.70E-09, 1.34E-07 mGy in 223Ra. The minimum uterus dose with 7.03E-09 mGy was determined in 89Sr treatment. It is observed that 223Ra produces low critical organ doses in the treatment of painful bone metastasis. Among the beta-emitting radionuclides, 89Sr stands out by showing optimal dosimetric results.

Adaptive radiation therapy (art) for patients with limited-stage small cell lung cancer (LS-SCLC): A dosimetric evaluation.

Adaptive radiation therapy (ART) refers to redesigning of radiation therapy (RT) treatment plans with respect to dynamic changes in tumor size and location throughout the treatment course. In this study, we performed a comparative volumetric and dosimetric analysis to investigate the impact of ART for patients with limited-stage small cell lung cancer (LS-SCLC). Twenty-four patients with LS-SCLC receiving ART and concomitant chemotherapy were included in the study. ART was performed by replanning of patients based on a mid-treatment computed tomography (CT)-simulation which was routinely scheduled for all patients 20-25 days after the initial CT-simulation. While the first 15 RT fractions were planned using the initial CT-simulation images, the latter 15 RT fractions were planned using the mid-treatment CT-simulation images acquired 20-25 days after the initial CT-simulation. In order to document the impact of ART, target and critical organ dose-volume parameters acquired from this adaptive radiation treatment planning (RTP) were compared with the RTP based solely on the initial CT-simulation to deliver the whole RT dose of 60 Gy. Statistically significant reduction was detected in gross tumor volume (GTV) and planning target volume (PTV) during the conventionally fractionated RT course along with statistically significant reduction in critical organ doses with incorporation of ART. One-third of the patients in our study who were otherwise ineligible for curative intent RT due to violation of critical organ dose constraints could be treated with full dose irradiation by use of ART. Our results suggest significant benefit of ART for patients with LS-SCLC.

From organ at risk to target organ: Dosimetric comparison of myocardial stereotactic ablative body radiotherapy between helical tomotherapy and volumetric arc therapy for refractory ventricular tachycardia.

Ventricular tachycardia (VT) is an important type of arrhythmia with a risk of sudden death. Although implanted cardiac defibrillation and radiofrequency ablation are used together with medical treatments for VT, the treatment options are limited in cases that do not respond to them. Stereotactic ablative body radiotherapy (SABR) applied to VT substrates in resistant cases is an emerging treatment with positive results. Such clinical results have increased the interest in this subject. However, the ideal treatment device and method have not yet been described for this therapy, which is generally applied at a single fraction using various devices and methods. Herein, treatment planning was conducted for a total of 8 patients (11 VT substrates) using the Varian TrueBeam EDGE and TomoTherapy Radixact devices at a single center, and the results were compared dosimetrically. The Wilcoxon-signed rank test was used for the statistical analysis, and mean values were expressed as medians and interquartile ranges (IQRs). In the volumetric modulated arc therapy (VMAT) and helical tomotherapy (HT) plans, the plan coverages and conformity indexes were similar; meanwhile, the homogeneity indexes were 0.10 (IQR = 0.05) and 0.07 (IQR = 0.05), respectively, and were significantly better in the HT plan (p = 0.02). The gradient indexes were 3.18 (IQR = 0.8) and 5.33 (IQR = 3.68) in the VMAT and HT plans, respectively, and were significantly better in the VMAT plan. For the organs at risk, similar doses were observed. The maximum doses for the stomach and esophagus and the mean doses for the left lung and both lungs were significantly lower in the VMAT plan. Similarly, the maximum and mean doses for the cardiac substructures and great vessels were significantly lower in the VMAT plan. More homogeneous plans were obtained in HT, while a faster dose reduction and lower critical organ dose were observed in VMAT. Reasonable myocardial SABR plans could be obtained with both techniques. The effects of the dosimetric differences on the clinical outcomes should be evaluated in prospective clinical studies.

Pretreatment Spinal Column Dose Estimation for Spinal SBRT Using Octavius Four-dimensional Phantom and Dose-volume Histograms Four-dimensional Feature: A Dosimetric Analysis.

The aim of this study was to estimate the spinal column dose for spinal Stereotactic body radiation therapy (SBRT) before patient treatment using the PTW dosimetry Octavius dose-volume histograms (DVH) four-dimensional (4D) feature. Twenty-three patients were included in the study, and a volumetric modulated arc therapy plan with 6MV flattening filter-free (6FFF) was generated for each patient in the Eclipse planning system using the Anisotropic Analytical Algorithm (AAA) algorithm (Varian Medical Systems, Palo Alto, CA) for the TrueBeam STx LINAC machine. The Octavius 4D system was used to estimate the spinal cord dose by delivering the plans to the 4D phantom. The measured dose was compared with the Eclipse treatment planning system (TPS) (Varian Medical Systems, Palo Alto, CA) dose. The spinal cord max and mean doses estimated using Varisoft DVH 4D are in close agreement with the TPS calculated max and mean doses. The deviation between measured dose and TPS dose is ±5% for the spinal max dose, and the deviation between measured dose and TPS dose is ± 3% for the spinal mean dose. The study demonstrates that the PTW Octavius 4D phantom and DVH 4D feature can be used as a tool to estimate spinal cord dose before the treatment in spinal SBRT plans. The system provides an independent dose measurement that is comparable to the TPS dose. The close agreement between measured and calculated doses validates the use of this system as a critical organ dose verification tool.

Dosimetric Comparison of Total Body Irradiation and Total Marrow Irradiation Using Volumetric Arc Therapy (VMAT)

Bu araştırmada tüm vücut ışınlaması (TVI) ve tüm kemik iliği ışınlaması (TKI) için, Volümetrik Ark Tedavi (VMAT) tekniği kullanılarak, hedef hacim ve kritik organ dozlarının karşılaştırılması amaçlanmıştır. Çalışmada, insan doku ve organ yoğunluklarına sahip, rando fantom kullanıldı. VMAT planları günlük fraksiyon dozu 6 Gy olmak üzere toplam doz 12 Gy olacak şekilde, oluşturuldu. Hedef hacimler ve risk altındaki organların (RAO) aldığı doz değerleri karşılaştırıldı. VMAT-TVI için ortalama akciğer dozu, 7.6 Gy ve lens dozu 4.4 Gy iken, VMAT-TKI için, RAO’nun dozları 2.7 ila 7.15 Gy aralığındadır. Ayrıca her iki plan için tedavi öncesi kalite kontrolü Octavius 4D fantom kullanılarak, planlanan ve verilen dozlar arasında doz doğruluğu, her 3 düzlemde 3mm ve %3 kriterleri ile gama indeks analizi, her iki tedavi planı için ≤1 olduğu saptanmıştır. Planlanan ve uygulanan tedavi arasında oldukça hassas doz dağılımı olduğu gözlemlendi. Her iki tedavi tekniğinde de hedef volüm istenilen dozu aldığı, fakat VMAT-TVI tekniğinde, doz homojenliği ve tedavi uygulama tekniklerinin iyileştirilmesi gerektiği sonucuna varıldı. TKI ile akciğer dışındaki diğer RAO'ların da daha iyi korunabildiği saptandı. Çalışmamızın sonucunda, VMAT'ın gelecekte geleneksel tekniklere göre hem TVI hem de TKI uygulaması için uygun bir teknik olabileceği görüşüne varıldı.

Attributable patient risk in nuclear medicine procedures and establishment of diagnostic reference levels.

The assessment of risk related to medical exposures as a justification tool to assist decision-making of the medical team is not available in clinical routine. The determination of diagnostic reference levels (DRLs) for nuclear medicine (NM) procedures has been proposed as an optimization tool, but this tool has still been aimed at a standard adult individual. It is known that the activity administered, and the consequent absorbed doses in critical organs, represents the risk of a procedure being cancer induction the greatest concern, especially for young patients. Thus, the adjustment of administered activity and procedure risk to promote risk-benefit assessment is a promising tool for routine clinical use. This work aims to present a tool for determining DRLs in the administered activity related to the patient's characteristics-age group, sex, and body mass index (BMI), in order to assist the medical decision regarding the risk-benefit ratio. Thus, it is possible to assess the risk of carcinogenesis in groups of patients, considering absorbed doses in organs, cancer incidence, and mortality rates in our country. NIREA is an IT tool developed in PHP language for web environment as a friendly software. It allows the establishment of DRL and risk of cancer induced by radiation assessment through the estimation of absorbed doses in specific organs and based on the risk methodology of BEIR VII. The absorbed and effective doses were estimated based on the dose conversion factors of the radiopharmaceuticals published by the International Commission on Radiological Protection adjusted for the patient groups. Based on data from 2256 patients who underwent diagnostic procedures at National Cancer Institute between 2017 and 2019, the program was used, resulting in important information for conducting the clinical routine extracted as DRL, absorbed doses, and risk assessments, considering patient-specific data such as age, sex, and BMI. The methodology developed in this work allows NM services to keep their data available and updated regarding local DRLs, in addition to allowing the nuclear physician to know the risk of each procedure performed, extracted by individual characteristics of the patient. The affirmative is significant because the data could be used by the regulatory body of practices with ionizing radiation in Brazil to establish a reference level in Activity that has not yet existed in the country.

A dosimetric comparison for SBRT plans of localized prostate cancer between Cyberknife and Varian Truebeam STX device

As the Stereotactic Body Radiotherapy (SBRT) approach began to increase in treating patients with localized prostate cancer, it became necessary to investigate which methods used in practice were better. The aim of this study is to perform a dosimetric comparison of the advantages and disadvantages of SBRT treatments for localized prostate cancer delivered by CyberKnife (CK) and Varian Truebeam STX (FF and FFF). Seventeen intermediate and high-risk patients with localized prostate cancer were included in the study. SBRT plans for the CK system and Varian Truebeam STX systems with and without Flattening Filters (Tru-FF and Tru-FFF) were prepared for each patient. Plans prepared for each patient were planned at a fraction dose of 6.7 Gy at 6 MV energy and a target dose of 33.5 Gy in 5 fractions. For all plans, cumulative dose-volume histograms (DVHs) were generated for target volumes and organs at risk (OAR). The maximum doses of PTV (41 Gy) in CK plans are higher than the maximum doses (35 Gy) in VMAT plans prepared with Tru-FF or Tru-FFF beams. The mean dose of the rectal wall (10.06 ± 2.40Gy for CK) is still relatively low compared to other plans (13.46 ± 2.16 Gy for Tru-FF and 13.61 ± 2.32 Gy for Tru-FFF). The bladder wall (14 Gy for CK, 26 Gy for Tru-FF and Tru-FFF) and femoral head (6.8 Gy for CK, 9 Gy for Tru-FF and 9.4 Gy Tru-FFF) doses were also lower for CK plans. The CK plans provide better tumour control due to low doses in critical organs and high target doses than the Tru-FF or Tru-FFF plans. It was observed that CK and VMAT plans for SBRT with 6 MV photon beams provided acceptable results in term of treatment planning criteria such as Conformity Index and Homogeneity Index. It is recommended to use a target tracking system to provide an accurate and reliable SBRT treatment with VMAT and CK techniques.

Comparison between MCNP and planning system in brachytherapy of cervical cancer

Absorbed doses in uterus during brachytherapy were calculated with MCNP in relevant points and compared with planning system for one patients. MCNP was applied with two different humanoid phantoms in input, ORNL and voxel models, which represent human body in mathematical way. Good agreement between both phantoms, as well as, between MCNP and planning system were found.In addition the doses in critical organs (bladder and colon in this kind of therapy), were calculated and compared with maximal doses in these organs obtained from planning system for 15 other patients. MCNP doses agree well with planning system in points of uterus for those 15 patients, where radioactive source is used to apply. However, there are systematical discrepancies between doses in colon and bladder obtained by MCNP and planning system.